Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Biliary Cirrhosis, Primary Clear all
Completed Phase 2 Interventional Results available

Use of Fenofibrate for Primary Biliary Cirrhosis

NCT00575042
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jun 10, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

NCT02477462
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Clinic visit, Baseline visit
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jun 10, 2026, 5:29 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT06525311
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis
Interventions
K-808
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jun 10, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Elafibranor 80mg, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Jun 10, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

NCT00006168
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Methotrexate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jun 10, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)

NCT00943176
View directory record Official record
Conditions
Fatigue, Primary Biliary Cirrhosis
Interventions
Modafinil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jun 10, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biobank for Cholestatic Liver Diseases.

NCT03445585
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
9,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

NCT05393076
View directory record Official record
Conditions
Pruritus
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

NCT02955602
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Coronado, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Tetrathiomolybdate, Placebo
Drug · Other
Lead sponsor
George Brewer
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

Moexipril for Primary Biliary Cirrhosis

NCT00588302
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Moexipril
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Jun 10, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

NCT03155932
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
APD334
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 10, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional

SAMe to Treat Biliary Cirrhosis Symptoms

NCT00125281
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
S-adenosyl-methionine (SAMe) capsules
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 5:29 PM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

NCT05104853
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
CNP-104, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Coronado, California • Lancaster, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jun 10, 2026, 5:29 PM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 10, 2026, 5:29 PM EDT